Study Reveals Equipment Behind “Microbiota Fecal Transmission”

Clostridioides difficile infection (rCDI) occurs in the spleen and is caused by the spore-forming anaerobic bacterium Gram-posta, C. difficile when its spores attach to fecal matter and handed over by health care workers.

Patients receiving antibiotic treatment are particularly vulnerable because the microorganisms that keep a healthy gut are severely damaged by the antibiotics.

Treatment of rCDI involves removing the causative antibiotics and initiating antibiotic therapy, although this can be quite challenging. Fecal microbiota transmission (FMT) is considered an effective alternative as it treats the issue from the ground up by replacing the damaged microflora with a healthy one through stool replacement. .

However, two deaths caused by antibiotic-resistant bacterial infections after FMT were reported in 2019, suggesting that a modification of FMT or alternatives is needed to address safety concerns regarding treatment.

Researchers at Osaka City University and the Institute for Medical Science, University of Tokyo addressed this challenge in a major study now published in gastroenterology.

Using their initial analytical pipeline reported in 2020, the researchers obtained bacterial and viral metagenome information from the fecal samples of nine rCDI patients from Brigham and Boston Women’s Hospital who successfully had FMT. . They revealed the bacteria and pathogens involved in the pathogenesis of rCDI and the remarkable pathways that are important for overcoming intestinal flora function.

By showing how the bacteriome and virome in the womb work together as an organ, the research team was able to show how FMT can be as safe as dislodging a bad organ with a good one .

Intestinal microbiota should definitely be treated as an ‘organ’. FMT has significantly altered the intestinal bacteriome and virome and is sure to restore the bacterial and viral intestinal functions. “

Satoshi Uematsu, Professor and Principal Investigator, Osaka City University

In the post-COVID-19 world, rCDI is going to be one of the most important international diseases. There is no doubt that FMT is an important therapeutic strategy for rCDI. “In addition to several clinical studies, complete metagenomic analysis is very important in considering the safety of FMT.” Say Dr. Kosuke Fujimoto and Professor Seiya Imoto.